Tenofovir in HIV/HBV Coinfection (TICO)
This study has been completed.
Sponsor:
Kirby Institute
Collaborators:
The University of New South Wales
Gilead Sciences
Information provided by:
Kirby Institute
ClinicalTrials.gov Identifier:
NCT00192595
First received: September 11, 2005
Last updated: April 8, 2008
Last verified: April 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130302074156im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
The purpose of the study is to compare the effectiveness of 3 different treatment regimens in reducing or clearing the Hepatitis B Virus in patients infected with HIV and Hepatitis B (co-infection)
Condition | Intervention | Phase |
---|---|---|
HIV Infection Hepatitis B Coinfection |
Drug: Tenofovir |
Phase 4 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Virological and Clinical Anti-HBV Efficacy of Tenofovir in Antiretroviral naïve Patients With HIV/HBV co-Infection |
Resource links provided by NLM:
Further study details as provided by Kirby Institute:
Primary Outcome Measures:
- To compare HBV DNA suppression to levels below the limit of detection (<400 copies/ml) by week 48 in each group
Secondary Outcome Measures:
- -HBV resistance at 48 weeks; -undetectable HBV DNA at weeks 12 & 24; -HBeAg and HBsAg seroconversion at weeks 24 & 48; -ALT chnages and rate of hepatic cytolysis; -HIV-1 RNA supression and CD4/CD8 changes over 48 weeks;
Enrollment: | 36 |
Study Start Date: | January 2004 |
Study Completion Date: | January 2007 |
Primary Completion Date: | January 2007 (Final data collection date for primary outcome measure) |
A randomised multi-centre trial of tenofovir vs lamivudine vs tenofovir/lamivudine in antiretroviral naïve subjects with HIV/HBV co-infection over 48 weeks (Clinical Trial A). Plus, a 12 week viral kinetic sub-study comparing a sub-group of the patients on Clinical Trial A with a group of therapy naïve HBV mono-infected subjects (Substudy A1)
![](https://webarchive.library.unt.edu/web/20130302074156im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Written informed consent
- Documented HIV infection (positive serology for HIV-1 and detectable HIV-1 RNA)
- Age 18 - 70 years
- HBV DNA > 105 copies/ml
- HBsAg positive >6 months or HBsAg positive and anti HB core IgM negative
- Creatinine <= 2.0mg/dl (<= 0.2 mmol/L)
- Platelet count >= 50,000/mm
- HIV-1 antiretroviral therapy naïve
- No prior exposure to anti-HBV agents (LAM, adefovir, TDF) although prior IFN treatment allowed
Exclusion Criteria:
- HCV-RNA positive or Anti-HAV IgM positive
- Acute hepatitis (serum ALT > 1000 U/L)
- Active opportunistic infection
- Other causes of chronic liver disease identified (autoimmune hepatitis, hemochromatosis, Wilsons disease, alfa-1-antitrypsin deficiency)
- Concurrent malignancy requiring cytotoxic chemotherapy
- Decompensated or Child's C cirrhosis
- Alfa-fetoprotein (AFP) > 3X ULN (unless negative CT scan or MRI within 3 months of entry date)
- Pregnancy or lactation
- Any other condition which in the opinion of the investigator might interfere with compliance or outcome of the study
![](https://webarchive.library.unt.edu/web/20130302074156im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Please refer to this study by its ClinicalTrials.gov identifier: NCT00192595
Locations
Australia, New South Wales | |
St. Vincent's Hospital | |
Darlinghurst, New South Wales, Australia, 2010 | |
Australia, Victoria | |
The Alfred Hospital | |
Melbourne, Victoria, Australia, 3004 | |
Thailand | |
Thai Red Cross AIDS Research Centre | |
Bangkok, Thailand |
Sponsors and Collaborators
Kirby Institute
The University of New South Wales
Gilead Sciences
Investigators
Principal Investigator: | Greg Dore, MBBS, FRACP | National Centre in HIV Epidemiology and Clinical Research |
![](https://webarchive.library.unt.edu/web/20130302074156im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Additional Information:
No publications provided by Kirby Institute
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | A/Prof Gregory J Dore, National Centre in HIV Epidemiology and Clinical Research, Univeristy of New South Wales |
ClinicalTrials.gov Identifier: | NCT00192595 History of Changes |
Other Study ID Numbers: | VHWG001, TICO |
Study First Received: | September 11, 2005 |
Last Updated: | April 8, 2008 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration Thailand: Ministry of Public Health |
Keywords provided by Kirby Institute:
Hepatitis B HIV Treatment Naive |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Hepatitis Hepatitis A Hepatitis B Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Liver Diseases |
Digestive System Diseases Hepatitis, Viral, Human Enterovirus Infections Picornaviridae Infections Hepadnaviridae Infections DNA Virus Infections Tenofovir Tenofovir disoproxil Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-Retroviral Agents Antiviral Agents |
ClinicalTrials.gov processed this record on February 28, 2013